Industry Partnerships
In 2024, Neurimmune entered into a collaboration agreement with NSC Therapeutics GmbH to further develop the M1 muscarinic agonist NSC001. NSC Therapeutics GmbH received $5 mio funding from the Alzheimer’s Disease Drug Discovery Foundation to support upcoming Phase 2 proof of concept clinical trials.
In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, to develop NI006, an investigational human monoclonal antibody specifically targeting misfolded transthyretin. In addition, Neurimmune expanded its drug discovery collaboration with Ono Pharmaceutical in the field of neurodegenerative diseases.
In 2020, Neurimmune and Ethris entered into a collaboration to develop an inhalable mRNA-based antibody therapy for the treatment of Covid-19, by combining antibodies identified using Neurimmune's RTM platform with ethris SNIM-RNA technology.
In 2019, Neurimmune and REGENXBIO initiated a collaboration to develop vectorized human antibodies for chronic neurodegenerative diseases, including tauopathies, by combining antibodies identified using Neurimmune's RTM platform with REGENXBIO's NAV technology.
In 2019, Neurimmune invested in the Series A financing round of NovaGo Therapeutics together with Pureos Bioventures. Neurimmune previously entered into a strategic partnership with Novago Therapeutics to develop human antibodies targeting Nogo-A for stroke and spinal cord injury.
In 2018, Neurimmune and NeuroScios co-founded NSC Therapeutics GmbH with the aim to develop a small chemical analogue (NSC001) of acetylcholine for the treatment of neurodegenerative diseases with cholinergic deficits such as Alzheimer's disease and dementia with Lewy bodies.
In 2017, Neurimmune entered into a research collaboration agreement with Ono Pharmaceutical (Japan) to discover and develop human monoclonal antibodies for neurodegenerative diseases.
In 2016, Neurimmune and Biogen further extended their collaboration by adding Neurimmune's antibody programs on C9orf72 for the treatment of ALS and fronto-temporal dementia.
In 2016, Neurimmune and TVM Capital Life Science jointly founded and financed AL-S Pharma AG. AL-S Pharma develops to proof-of-concept AP-101 (NI005), a human monoclonal antibody targeting misfolded SOD1 for the treatment of amyotrophic lateral sclerosis (ALS) that was generated and pre-clinically validated by Neurimmune’s Reverse Translational Medicine platform.
In 2010, Neurimmune entered into a second deal with Biogen, with an additional aggregate volume of more than $430 million for the worldwide rights to three immunotherapy programs addressing alpha-synuclein, tau and TDP-43. These are believed to be central targets for the treatment and prevention of a wide variety of neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS).
In 2007, Neurimmune entered into an agreement with Biogen, a leading biopharmaceutical company to develop and commercialize novel treatments for Alzheimer’s disease with an aggregate deal volume of $386 million plus royalties on net sales.
